Coupler

Triumvira Immunologics is a clinical-stage immunotherapy company focused on developing a novel class of T cell therapies for the treatment of solid and liquid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology is designed to co-opt the natural biology of T cells, recruiting the entire natural T cell receptor complex to provide a more controlled and potentially safer anti-tumor response compared to traditional CAR-T therapies. Their lead candidate, TAC01-HER2, is currently in Phase 1/2 clinical trials for patients with HER2-positive solid tumors, including gastric and gastroesophageal cancers. Triumvira is also advancing a robust pipeline of autologous and allogeneic programs targeting antigens such as Claudin 18.2 and GPC3. Headquartered in Austin, Texas, the company maintains research and manufacturing facilities across North America to support its mission of delivering transformative cancer treatments.